Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: midazolam
Drug: BI 425809

First Posted Date: 2022-02-28

Last Posted Date: 2022-06-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT05258110

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Phase 1

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions: Drug: BI 765063
Drug: Ezabenlimab
Drug: Cetuximab
Other: Investigator´s Choice Chemotherapy
Drug: BI 836880

First Posted Date: 2022-02-21

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT05249426

Locations: 🇯🇵
Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 21 locations

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Phase 2

Completed

Conditions: Bronchiectasis

Interventions: Drug: Placebo
Drug: BI 1291583

First Posted Date: 2022-02-14

Last Posted Date: 2024-08-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 322

Registration Number: NCT05238675

Locations: 🇳🇱
Amsterdam UMC, location VUMC, Amsterdam, Netherlands
🇪🇸
Hospital de Mérida, Mérida, Spain
🇺🇸
Malcom Randall VA Medical Center, Gainesville, Florida, United States

and more 107 locations

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Phase 3

Completed

Conditions: Generalized Pustular Psoriasis

Interventions: Drug: spesolimab

First Posted Date: 2022-02-14

Last Posted Date: 2024-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT05239039

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
🇨🇳
Beijing Friendship Hospital, Beijing, China
🇨🇳
West China Hospital, Chengdu, China

and more 9 locations

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Active, not recruiting

Conditions: Heart Failure

Interventions: Drug: JARDIANCE®

First Posted Date: 2022-02-11

Last Posted Date: 2024-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 600

Registration Number: NCT05236673

Locations: 🇰🇷
Hallym University Medical Center, Anyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Inje University Haeundae Paik Hospital, Busan, Korea, Republic of

and more 18 locations

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 2

Active, not recruiting

Conditions: Liposarcoma, Dedifferentiated

Interventions: Drug: Brigimadlin (BI 907828)
Drug: Doxorubicin

First Posted Date: 2022-02-01

Last Posted Date: 2024-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 401

Registration Number: NCT05218499

Locations: 🇺🇸
City of Hope-Duarte-56419, Duarte, California, United States
🇺🇸
Nebraska Cancer Specialists-Omaha-69502, Omaha, Nebraska, United States
🇦🇺
Prince of Wales Hospital-Randwick-66496, Randwick, New South Wales, Australia

and more 105 locations

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

Phase 2

Active, not recruiting

Conditions: Kidney Disease, Chronic

Interventions: Drug: BI 764198
Drug: Placebo

First Posted Date: 2022-01-28

Last Posted Date: 2024-11-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 67

Registration Number: NCT05213624

Locations: 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

and more 45 locations

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Phase 3

Recruiting

Conditions: Schizophrenia

Interventions: Drug: BI 425809

First Posted Date: 2022-01-27

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1401

Registration Number: NCT05211947

Locations: 🇭🇺
Semmelweis University, Budapest, Hungary
🇺🇸
Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸
Clinical Innovations, Inc, Bellflower, California, United States

and more 296 locations

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 695501 - higher concentration
Drug: BI 695501 - lower concentration

First Posted Date: 2022-01-24

Last Posted Date: 2024-03-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT05203289

Locations: 🇺🇸
QPS MO, Springfield, Missouri, United States
🇺🇸
Miami Research Associates, Inc, Miami, Florida, United States

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: BI 456906
Drug: Semaglutide

First Posted Date: 2022-01-21

Last Posted Date: 2024-11-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT05202353

Locations: 🇳🇱
Amsterdam UMC, location VUMC, Amsterdam, Netherlands

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy